Completely agree with that take. One wouldn't think the FDA would be inclined to significantly lower the age of the target population if they were otherwise going to reject the NDA. (Obviously doesn't guarantee approval but I agree with you that it's a very good sign.)
Along with this good news today, DVAX market cap is now above $500M. So, the key of course is what's a reasonable munch price? You think they could fetch a cool $1B (or more) in a takeout? I'd much rather DVAX be around $300M market cap here but I'm cheap. ; ) Still, very good news today and I just wonder what further upside is if a buyout should occur. (Guess part of this is based on how much of that estimated $1B market you think Heplisav can now capture.)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.